Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Bi-Est (1:1)

Lack of Processing Control

Terminated cGMP deviation The Medicine Shoppe Pharmacy D-1189-2020
Class II · Moderate risk

Bi-Est (1:1)

Lack of Processing Control

Terminated cGMP deviation The Medicine Shoppe Pharmacy D-1188-2020
Class II · Moderate risk

Bi-Est (8:2)

Lack of Processing Control

Terminated cGMP deviation The Medicine Shoppe Pharmacy D-1187-2020
Class II · Moderate risk

Bi-Est (1:1)

Lack of Processing Control

Terminated cGMP deviation The Medicine Shoppe Pharmacy D-1186-2020
Class II · Moderate risk

Naltrexone

Lack of Processing Control

Terminated cGMP deviation The Medicine Shoppe Pharmacy D-1180-2020
Class II · Moderate risk

Fluorouracil

Lack of Processing Control

Terminated cGMP deviation The Medicine Shoppe Pharmacy D-1177-2020
Class II · Moderate risk

Doxycycline Capsules

CGMP Deviations: Doxycycline capsules were not manufactured under Current Good Manufacturing Practice conditions.

Terminated cGMP deviation Sun Pharmaceutical Industries, Inc. NDC 63304-616-50 D-1033-2020
Class II · Moderate risk

Doxycycline Capsules

CGMP Deviations: Doxycycline capsules were not manufactured under Current Good Manufacturing Practice conditions.

Terminated cGMP deviation Sun Pharmaceutical Industries, Inc. NDC 63304-615-01 D-1032-2020
Class II · Moderate risk

Morphine Sulfate

Lack Of Processing Controls

Terminated cGMP deviation Redline Pharmacy Solutions D-1011-2020
Class II · Moderate risk

Daptomycin

Lack Of Processing Controls

Terminated cGMP deviation Redline Pharmacy Solutions D-1008-2020
Class II · Moderate risk

Morphine Sulfate

Lack Of Processing Controls

Terminated cGMP deviation Redline Pharmacy Solutions D-1007-2020